Identification and Management of Diabetic Nephropathy in the Diabetes Clinic
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To examine the prevalence and management of diabetic nephropathy in a diabetes clinic. RESEARCH DESIGN AND METHODS—Characteristics of nephropaths identified by existing screening practice (phase I, albuminuria >20 mg/l in three separate urine samples), were compared with those identified by a nurse-led management program (phase II, in which screening for nephropathy was based on albumin-to-creatinine ratio in a single random urine specimen). RESULTS—In phase I, 644 patients attended a diabetes clinic over a 6-month period. Microalbuminuria results were available for 485 patients (75%). A total of 115 patients were identified as nephropaths (prevalence 17.8%). Of these patients, 91% had type 2 diabetes. During phase II, prospective analysis of urinary albumin-to-creatinine ratio was carried out in 880 patients over 8 months. A total of 174 patients were identified as nephropaths (prevalence 20%). Of these, 134 patients had been identified by existing screening protocols. Forty had no previous record of microalbuminuria and were therefore newly identified by prospective screening. Systolic blood pressure guidelines were met in only 31% of all known nephropaths and 26.5% of newly diagnosed nephropaths. Diastolic blood pressure guidelines were met in 36% of all known and 38% of newly diagnosed nephropaths. In the patient group of known nephropaths from phases I and II, 62% were prescribed ACE inhibitors (ACEIs) or angiotensin II receptor (AIIR) antagonists. In the newly identified nephropathy patient cohort from phase II, 48% used ACEIs or AIIR antagonists. CONCLUSIONS—Introduction of a nurse-led management program significantly improved detection of nephropathy. We are currently evaluating its impact on clinical management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 1×
“Secondary analysis in secondary prevention studies also suggests beneficial effects of treatment of hypercholesterolemia (35,36).”
Background(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
A Case-Management System for Coronary Risk Factor Modification after Acute Myocardial Infarction
DeBusk, R. F., Miller, N. H., Superko, H. R., Dennis, C. A., Thomas, R. J., Lew, H. T., Berger, W. E., Heller, R. S., Rompf, J., Gee, D., et al. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-9-199405010-00001 · Cited by 745
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Cited by
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Insights into predicting diabetic nephropathy using urinary biomarkers
Khan, N. U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., & Shen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140475 · Cited by 90
Voulgari, C., Katsilambros, N., & Tentolouris, N. (2011) · Metabolism · doi:10.1016/j.metabol.2011.02.014 · Cited by 90
Morello, C. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s26889 · Cited by 71
Metadata
- Authors
- Craig, K. J., Donovan, K., Munnery, M., Owens, D. R., Williams, J. D., & Phillips, A. O.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-06-01
- Volume
- 26
- Issue
- 6
- Pages
- 1806-1811
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2104100987
- Cited by
- 38
- References
- 8
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.